Microbot Medical announces FDA submission for commercialization of LIBERTY

Microbot Medical (MBOT) announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, FDA, for LIBERTY. LIBERTY is the world’s first single-use, fully disposable robotic system for endovascular procedures. The 510(k) submission follows the successful completion of its multi-center, single-arm, trial to evaluate the performance and safety of LIBERTY in human subjects undergoing Peripheral Vascular Interventions.